title: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
abstract: OBJECTIVE
  To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC).
  
  
  METHODS
  Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER-2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual-color fluorescence in-situ hybridization (FISH) assays.
  
  
  RESULTS
  Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications.
  
  
  CONCLUSIONS
  Trastuzumab (Herceptin) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC.
authors.affiliation: UCHSC, 4200 E. 9th Ave. C-319, Denver, CO, USA. al.barqawi@uchsc.edu
authors.forename: Ali
authors.initials: A
authors.lastname: Ziada
authors.forename: Albaha
authors.initials: A
authors.lastname: Barqawi
authors.forename: L Michael
authors.initials: LM
authors.lastname: Glode
authors.forename: Marileila
authors.initials: M
authors.lastname: Varella-Garcia
authors.forename: Frances
authors.initials: F
authors.lastname: Crighton
authors.forename: Susan
authors.initials: S
authors.lastname: Majeski
authors.forename: Mark
authors.initials: M
authors.lastname: Rosenblum
authors.forename: Madeleine
authors.initials: M
authors.lastname: Kane
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D017430:Prostate-Specific Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab